Anatumomab mafenatox

From WikiProjectMed
Jump to navigation Jump to search
Anatumomab mafenatox
Monoclonal antibody
TypeFab fragment
Clinical data
ATC code
  • none
CAS Number
  • none

Anatumomab mafenatox is a mouse monoclonal antibody studied for the treatment non-small cell lung cancer,[1] which acts as a tumor-targeted superantigen.[2]

It is a fusion protein of a human tumor-associated 5T4 antigen monoclonal IgG1 Fab fragment with an enterotoxin ('mafenatox') of Staphylococcus aureus.[3]

Development was abandoned in 2005.[4]


  1. ^ "Active Biotech". Retrieved 25 May 2016.
  2. ^ Hedlund G, Forsberg G, Nederman T, Sundstedt A, Dahlberg L, Tiensuu M, Nilsson M (2013). "Tumor-Targeted Superantigens". Fusion Protein Technologies for Biopharmaceuticals. pp. 365–381. doi:10.1002/9781118354599.ch24. ISBN 9781118354599.
  3. ^ "Drug info" (PDF). World Health Organization. Retrieved 25 May 2016.
  4. ^ "Anatumomab mafenatox". AdisInsight. Springer Nature Switzerland AG.